Details

Autor(en) / Beteiligte

• Lemoine, Maud
• Assoumou, Lambert
• Girard, Pierre-Marie
• Valantin, Marc Antoine
• Katlama, Christine
• De Wit, Stephane
• Campa, Pauline
• Rougier, Hayette
• Meynard, Jean-Luc
• Necsoi, Coca
• Huefner, Anja D.
• Van Luzen, Jan
• Schulze zur Wiesch, Julian
• Bastard, Jean-Philippe
• Fellahi, Soraya
• Mauss, Stefan
• Stankov, Metodi V.
• Baumgarten, Axel
• Post, Gerrit
• Serfaty, Lawrence
• Ratziu, Vlad
• Menu, Yves
• Schlue, Jerome
• Bedossa, Pierre
• Capeau, Jacqueline
• Costagliola, Dominique
• Behrens, Georg
• Ingiliz, Patrick

Titel

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Ist Teil von

• Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.713-722.e3

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Nonalcoholic fatty liver disease (NAFLD) is a growing concern in the aging population with human immunodeficiency virus (HIV). Screening for NAFLD is recommended in patients with metabolic risk factors or unexplained transaminitis. This study aimed to prospectively assess the prevalence and associated factors of liver steatosis and advanced fibrosis (AF) in HIV-monoinfected patients at risk of NAFLD. We conducted a multicenter study in HIV-monoinfected patients, nonexcessive drinkers with metabolic syndrome, and/or persistently elevated liver enzymes, and/or clinical lipodystrophy. All participants had magnetic resonance imaging proton density fat fraction (MRI-PDFF), Fibroscan/controlled attenuation parameter (CAP), and cytokine and genetic analysis. From March 2014 to November 2015, we enrolled 442 participants and analyzed 402: male (85%); median age, 55 years (interquartile range [IQR], 50-61 years); body mass index, 27.0 kg/m2 (IQR, 23.6-28.7 kg/m2); metabolic syndrome (67%); and CD4 cell count, 630/mm3 (IQR, 510-832/mm3). Overall 257 of 402 (64%) had NAFLD (MRI-PDFF ≥5%). Among them, 11.3% had a liver stiffness ≥9.6 kPa, suggestive of AF. Multivariable analysis identified 7 factors of steatosis: high CD4-cell count (odds ratio [OR], 4.04; 95% confidence interval [CI], 1.92–8.51), high leptin level (OR, 2.12; 95% CI, 1.14–3.93), non-CC PNPLA3s738409 genetic polymorphism (OR, 1.92; 95% CI, 1.11–3.33), low high-density lipoprotein (OR, 1.83; 95% CI, 1.03–3.27), high triglycerides (OR, 1.48; 95% CI, 1.18–1.84), elevated alanine transaminase (OR, 1.23; 95% CI, 1.16–1.31), and hyper ferritinemia (OR, 1.05; 95% CI, 1.03–1.07). Two factors were associated with AF: high body mass index (OR, 1.23 ; 95% CI, 1.07–1.42 ; P = .005, and elevated aspartate aminotransferase (OR, 1.03; 95% CI, 1.01–1.05; P = .001). Using MRI-PDFF as a reference, CAP (best cutoff, 280 dB/m) had good accuracy (area under the receiver operating characteristic curve = 0.86; 95% CI, 0.82–0.90) for the diagnosis of moderate to severe steatosis. In a large cohort of HIV-moninfected patients at risk of NAFLD, steatosis is present in two-thirds of cases, and around 10% have AF. The CAP technique is accurate for screening steatosis in this population. [Display omitted]